European Commission approves omalizumab as an add-on therapy for the treatment of adults with severe chronic rhinosinusitis with nasal polyps

The label extension is based on Phase III studies showing it improves symptoms and quality of life in patients with this condition, which affects up to 4% of people worldwide. Omalizumab blocks IgE which is a key driver in the inflammatory pathway of the disease.

PharmaTimes